James F. Howard

13.1k total citations · 2 hit papers
204 papers, 6.2k citations indexed

About

James F. Howard is a scholar working on Neurology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, James F. Howard has authored 204 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Neurology, 31 papers in Infectious Diseases and 27 papers in Molecular Biology. Recurrent topics in James F. Howard's work include Myasthenia Gravis and Thymoma (129 papers), Peripheral Neuropathies and Disorders (76 papers) and Antifungal resistance and susceptibility (30 papers). James F. Howard is often cited by papers focused on Myasthenia Gravis and Thymoma (129 papers), Peripheral Neuropathies and Disorders (76 papers) and Antifungal resistance and susceptibility (30 papers). James F. Howard collaborates with scholars based in United States, Italy and United Kingdom. James F. Howard's co-authors include Donald B. Sanders, Gary M. Franklin, Janice M. Massey, Richard A. Lewis, A. J. Sumner, L. J. Kinsella, William P. Cheshire, E W Massey, César Santos and Jeffrey A. Cohen and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

James F. Howard

189 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Distal symmetric polyneuropathy: A definition for clinical research

2005 566 citations James F. Howard et al. Neurology profile →
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

2024 36 citations James F. Howard, Vera Bril et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James F. Howard United States	40	3.7k	860	835	788	776	204	6.2k
Richard J. Barohn United States	37	4.5k 1.2×	950 1.1×	276 0.3×	772 1.0×	697 0.9×	114	6.1k
Martina Fabris Italy	37	782 0.2×	646 0.8×	950 1.1×	623 0.8×	768 1.0×	146	4.5k
Janice M. Massey United States	31	3.4k 0.9×	1.1k 1.3×	219 0.3×	642 0.8×	357 0.5×	90	5.8k
Thierry Küntzer Switzerland	29	1.1k 0.3×	198 0.2×	644 0.8×	537 0.7×	1.5k 2.0×	178	5.0k
Donald B. Sanders United States	52	8.6k 2.3×	1.9k 2.2×	300 0.4×	1.4k 1.8×	784 1.0×	189	10.7k
Sven Saussez Belgium	46	1.2k 0.3×	680 0.8×	701 0.8×	1.3k 1.6×	1.3k 1.6×	270	8.0k
G. Parry United Kingdom	40	1.7k 0.5×	133 0.2×	734 0.9×	1.6k 2.1×	1.2k 1.5×	181	6.3k
Jeffrey M. Gelfand United States	38	1.7k 0.5×	139 0.2×	572 0.7×	224 0.3×	823 1.1×	110	4.8k
Dominique Hénin France	44	692 0.2×	425 0.5×	417 0.5×	1.2k 1.5×	1.1k 1.4×	156	5.7k
Francesco Tomasello Italy	43	1.9k 0.5×	182 0.2×	276 0.3×	1.2k 1.5×	766 1.0×	243	5.9k

Countries citing papers authored by James F. Howard

Since Specialization

Citations

This map shows the geographic impact of James F. Howard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James F. Howard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James F. Howard more than expected).

Fields of papers citing papers by James F. Howard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James F. Howard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James F. Howard. The network helps show where James F. Howard may publish in the future.

Co-authorship network of co-authors of James F. Howard

This figure shows the co-authorship network connecting the top 25 collaborators of James F. Howard. A scholar is included among the top collaborators of James F. Howard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James F. Howard. James F. Howard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hewamadduma, Channa, Miriam Freimer, Angela Genge, et al.. (2025). Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. Journal of Neurology. 272(7). 457–457. 2 indexed citations

Hajhosseiny, Reza, Camila Muñoz, Amarjit Sethi, et al.. (2025). Free-breathing, non-contrast, three-dimensional whole-heart coronary magnetic resonance imaging for the identification of culprit and vulnerable atherosclerotic plaque. Journal of Cardiovascular Magnetic Resonance. 27(1). 101898–101898.

Nowak, Richard J., Ali A. Habib, Andrew J. Klink, et al.. (2024). US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization. Drugs - Real World Outcomes. 11(4). 593–601. 1 indexed citations

Dewilde, Sarah, Alison Griffiths, Cynthia Z. Qi, et al.. (2024). Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis. Journal of the Neurological Sciences. 466. 123264–123264. 7 indexed citations

Habib, Ali A., Andrew J. Klink, Srikanth Muppidi, et al.. (2024). United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use. Journal of Neurology. 271(9). 6114–6126. 6 indexed citations

Brandsema, John F., Hideki Hoshino, Masakazu Mimaki, et al.. (2024). Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study. Pediatric Neurology. 156. 198–207. 7 indexed citations

Mann, Joshua R., Yanan Zhang, Suzanne McDermott, et al.. (2023). Racial and Ethnic Differences in Timing of Diagnosis and Clinical Services Received in Duchenne Muscular Dystrophy. Neuroepidemiology. 57(2). 90–99. 8 indexed citations

Vu, Tuan, Andreas Meisel, Renato Mantegazza, et al.. (2023). Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. Neurology and Therapy. 12(5). 1435–1438. 14 indexed citations

Guptill, Jeffrey T., Michael Benatar, Volkan Granit, et al.. (2023). Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials. Neurology. 101(10). 442–451. 15 indexed citations

10.

Bril, Vera, James F. Howard, Chafic Karam, et al.. (2023). Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study. European Journal of Neurology. 31(1). e16098–e16098. 12 indexed citations

11.

Pham, Minh, Sangwook Oh, Aimee Payne, et al.. (2023). Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis. Annals of Clinical and Translational Neurology. 10(5). 825–831. 11 indexed citations

12.

Vu, Tuan, Stephan Ortiz, Masahisa Katsuno, et al.. (2022). Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults with Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Study (P3-1.002). Neurology. 98(18_supplement). 2 indexed citations

13.

Wang, Yan, Mandy I. Cheng, Willy Hugo, et al.. (2022). Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunity. Proceedings of the National Academy of Sciences. 119(4). 22 indexed citations

14.

Howard, James F., John Vissing, Nils Erik Gilhus, et al.. (2021). Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis. Expert Opinion on Investigational Drugs. 30(5). 483–493. 47 indexed citations

15.

Howard, James F., Vera Bril, Tuan Vu, et al.. (2021). Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520). Neurology. 96(15_supplement). 9 indexed citations

16.

Kaminski, Henry J., et al.. (2020). Complement Inhibitor Therapy for Myasthenia Gravis. Frontiers in Immunology. 11. 917–917. 50 indexed citations

17.

Wang, Yan, et al.. (2018). IL-10 Paradoxically Promotes Autoimmune Neuropathy through S1PR1-Dependent CD4+ T Cell Migration. The Journal of Immunology. 200(5). 1580–1592. 15 indexed citations

18.

Hehir, Michael K., Lisa D. Hobson‐Webb, Michael Benatar, et al.. (2017). Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology. 89(10). 1069–1077. 166 indexed citations

19.

Howard, James F., et al.. (2008). The Ventilator Support of Patients with Neuromuscular Disorders. 62(1). 17–25.

20.

Navaneetham, Duraiswamy, et al.. (1997). Expression of the alpha 7 subunit of the nicotinic acetylcholine receptor in normal and myasthenic human thymuses.. PubMed. 43(3). 433–42. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact